Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity

Fig. 1 Full size image Teprotumumab is a monoclonal antibody therapy targeting insulin-like growth factor-1 receptor for active thyroid eye disease (TED) [ 1 , 2 ]. This infographic summarises the design and results of the phase VI multicentre trial which evaluated the efficacy, safety, and tolerability of teprotumumab in patients with longstanding TED (2-10 years disease duration) and low clinical disease activity (CAS ≤ 1) [ 2 ]. Teprotumumab reduced proptosis in patients with chronic TED [ 2 , 3 ].